Organon & Co.
OGNNYSEHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B | $6.53B |
| Operating income | — | — | — | — | — | — |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B | $2.16B |
| Total assets | $12.87B | $13.10B | $12.06B | $10.96B | $10.68B | $10.11B |
| Total liabilities | $12.12B | $12.63B | $12.13B | $11.85B | — | — |
| Equity | $752.0M | $472.0M | −$70.0M | −$892.0M | −$1.51B | $5.49B |
| EPS (diluted) | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 | $8.52 |
| Shares out. | 258.0M | 255.6M | 254.4M | 253.6M | 253.6M | 253.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- 3.0%
- Return on equity
- 24.9%
- Return on assets
- 1.5%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 94.2%
- Debt / equity
- 16.11×
- Book value / share
- $2.92
- Revenue growth (YoY)
- −2.9%
- Net income growth (YoY)
- −78.4%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −4.0%clean
- Beneish M-Score
- -2.65normal
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 3 good- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Strong return on equity (>15%)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- LIPTRUZETMay 3, 2013
- IMPLANONJul 17, 2006
- CLARINEX D 24 HOURMar 3, 2005
- VYTORINJul 23, 2004
- ZETIAOct 25, 2002
- CLARINEXDec 21, 2001
- MAXALT-MLTJun 29, 1998
- SINGULAIRFeb 20, 1998
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-10Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
- Phase 3Recruitingreadout ~2028-01A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Vanguard Portfolio Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Blackrock, Inc.Passive (13G)Apr 30, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 20.0M | 3.2 | +2.8% |
| Apr 30, 2026 | 19.5M | 1.0 | +4.8% |
| Apr 15, 2026 | 18.6M | 1.9 | -15.9% |
| Mar 31, 2026 | 22.1M | 6.0 | +14.5% |
| Mar 13, 2026 | 19.3M | 6.2 | +18.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsApr 30, 2026
- Entered a material agreement · Director / officer change · Regulation FD disclosureApr 27, 2026
- Other material eventFeb 20, 2026
- Results of operations · Regulation FD disclosureFeb 12, 2026
- Results of operations · Regulation FD disclosureNov 10, 2025
- Director / officer changeNov 7, 2025
- Director / officer change · Other material eventOct 27, 2025
- Results of operations · Regulation FD disclosureAug 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- PREM14AJun 1, 2026
- SDFORM SDMay 29, 2026
- 144May 8, 2026
- 4/AFORM 4/AMay 7, 2026
- 4FORM 4May 7, 2026
- 10-QMay 4, 2026
- SCHEDULE 13GApr 30, 2026
- DEFA14AApr 30, 2026
- DEFA14AApr 30, 2026
- 8-KFORM 8-KApr 30, 2026
- SCHEDULE 13GApr 29, 2026
- DEFA14AApr 27, 2026
- DEFA14AApr 27, 2026
- DEFA14AApr 27, 2026
- DEFA14AApr 27, 2026
Corporate family
Spun off from MerckMRK · Jun 1, 2021
From the spin-off filings we track. Follow a company to walk its own history.